Key Takeaways:
Law firm Kirby McInerney LLP is investigating Nano-X Imaging Ltd. after the company’s stock fell 25% following the announcement of a $17.5 million impairment charge. The probe focuses on whether the medical imaging technology company issued false or misleading statements to investors.
"The investigation concerns the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices," Kirby McInerney LLP stated in a press release issued April 27, 2026.
Nano-X shares dropped sharply from $2.85 on April 17 to $2.15 on April 20 after it reported a fourth-quarter 2025 net loss of $33.4 million. A significant portion of the loss was attributed to a $17.5 million impairment charge related to a restructuring at its Korean chip manufacturing facility. Compounding the negative news, the company also announced that its Chief Financial Officer, Ran Daniel, would be stepping down from his role effective July 31, 2026.
The investigation by Kirby McInerney, a firm specializing in securities litigation, adds significant legal risk on top of the company's recent financial instability. The 25% single-day price collapse reflects a sharp decline in investor confidence. The law firm is actively encouraging shareholders who incurred losses to come forward, a common precursor to the filing of a class-action lawsuit.
The Schall Law Firm also announced a similar investigation, focusing on whether the company failed to disclose pertinent information to investors. Both law firms are soliciting investors who purchased Nano-X securities and suffered losses to join their respective investigations.
This new probe creates further uncertainty for Nano-X, which has faced scrutiny in the past. The departure of a key executive combined with a significant asset write-down and the subsequent legal challenges present a difficult path forward for the company. Investors will be closely watching for the outcome of these investigations and any potential legal proceedings that may follow.
This article is for informational purposes only and does not constitute investment advice.
